Home › Gastrointestinal Cancers › NCT06159634

Traction vs. No Traction in Colonic ESD

Comparison of the Efficacy of Using a Traction Device in Colonic Endoscopic Submucosal Dissection Versus Conventional ESD: A Randomized Clinical Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Patient is ≥ 18 years old.
2. Patients can provide informed consent.
3. Patient is referred for ESD procedure of colonic neoplastic lesions and with one of the following criteria:

A- Lesions with prior resection or with scar at any size. B- Granular lateral spreading tumors (GLST) more than 3 cm. C- Non granular lateral spreading tumors (NGLST) more than 20 mm. D- Any suspected submucosal invasion such as Paris classification II a +II or lesions with positive non lifting sign.

Exclusion Criteria:

1. Patient is \< 18 years old.
2. Patient refused and/or unable to provide consent.
3. Patient is a pregnant woman.
4. Lesions with morphology: pedunculated type (Paris IP, Ips).
5. Appendiceal orifice or IC valve lesions. 6. Patients with lesions removed with other techniques besides ESD (like hybrid ESD or submucosal tunneling technique STER and EMR).

About the study

The goal of this prospective, randomized, controlled trial conducted at Baylor St. Luke's Medical Center is to compare the effectiveness and clinical outcomes of using a traction device in colonic endoscopic submucosal dissection (ESD) to those of using conventional ESD.

The investigators of this study hypothesize that use of the traction device will help expedite colonic endoscopic submucosal dissections.

What is being tested

• Endoscopic Submucosal Dissection (procedure)
• Traction Device (device)

Sponsor: Baylor College of Medicine · Participants: 150 · Started: Dec 5, 2023

Contact the study team

• Mai Khalaf, MD · Phone: 713-798-6696
• Michael Mercado, BS · Phone: 713-798-3606

Official record on ClinicalTrials.gov — NCT06159634

Locations in the U.S.

Conditions

• Gastrointestinal Cancers

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.